A Sanofi experimental drug for multiple sclerosis delayed disability progression in a late-stage trial, but failed to reduce episodes of new or worsening symptoms compared to an existing treatment ...

In 2022, the FDA placed Sanofi’s Phase 3 studies of tolebrutinib in multiple sclerosis and myasthenia gravis on partial clinical hold.

Sanofi’s experimental drug for a form of multiple sclerosis delayed the progression of disability by nearly a third, providing hope for patients for whom there’s currently no treatment.

Sanofi said an oral treatment for multiple sclerosis, tolebrutinib, met its key goal in a phase 3 study.

Sanofi ‘s most advanced multiple sclerosis drug candidate failed to achieve the main goal of two late-stage trials to treat relapsing forms of the disease. However, the drug was able to succeed ...

Sanofi has stopped a phase 2 trial of Denali Therapeutics-partnered oditrasertib in multiple sclerosis. The French drugmaker tore the RIPK1 inhibitor trial from its list of active studies after it ...

Denali Therapeutics said on Thursday its partner Sanofi has discontinued a mid-stage study testing their experimental drug to treat multiple sclerosis as it failed to meet the main and secondary ...

Sanofi's (SNY) tolebrutinib gains FDA priority review for multiple sclerosis treatment. Read more here, ...

(Reuters) -Sanofi's most advanced multiple sclerosis drug candidate has missed the main goal of two late-stage trials to treat relapsing forms of the disease, but in a positive surprise succeeded ...

Sanofi invites patients to ‘Rediscover MS’ with new educational site on disease progression By Andrea Park Oct 9, 2024 12:01pm Sanofi multiple sclerosis awareness patient education ...

A Sanofi experimental drug for multiple sclerosis delayed disability progression in a late-stage trial, but failed to reduce episodes of new or worsening symptoms compared to an existing treatment ...

In 2022, the FDA placed Sanofi’s Phase 3 studies of tolebrutinib in multiple sclerosis and myasthenia gravis on partial clinical hold.